Abstract. Palladin is a scaffold protein involved in the formation of actin-associated protein complexes. Gene expression array analysis on the poorly metastatic HCT116 colon cancer cell line and a metastatic derivative cell line (E1) with EMT (epithelial-mesenchymal transition) features showed a down-regulation of palladin gene expression in the latter. Knockdown of palladin expression in the HCT116 cells suppressed junctional localization of E-cadherin, reduced intercellular adhesion and collective cell migration, showing that palladin plays an important role in maintaining the integrity of adherens junctions. The acquisition of the EMT features by the E1 cell line was dependent on the Erk pathway. Inhibition of this pathway by U0126 treatment in E1 cells resulted in the re-expression of palladin, relocalization of E-cadherin to the adherens junctions and a reversal of EMT features. The re-establishment of intercellular adhesion was dependent on palladin expression. The down-regulation of palladin was also observed in poorly-differentiated tumor tubules and dissociated tumor cells that have undergone de-differentiation in human primary colon tumors. Our data show that palladin is an integral component of adherens junctions and plays a role in the localization of E-cadherin to the junctions. The loss of palladin may be an integral part of EMT, an early step in the metastatic spread of colon carcinoma.

Introduction

Colorectal cancer is one of the most common and deadly cancers in developed countries, accounting for approximately 8% of deaths from all cancers worldwide (1). Although surgical resection is highly effective for early stage tumors (with cure rates of over 90% in stage I and 75% in stage II disease), the treatment of advanced colon cancer with metastases remains essentially palliative, as these later stage malignancies respond poorly to current chemotherapeutic regimens (2). The genetic mechanisms underlying the adenoma-carcinoma progression in colon cancer are relatively well understood, and has been shown to involve the mutational activation of oncogenes (such as ras and myc) and suppression of tumor suppressor genes (such as Apc and p53). In contrast, although the physiological steps of metastasis (3,4) have been well-characterized, the molecular mechanisms for the progression from carcinoma - in situ to invasive and metastatic tumors are less clear. An understanding of the molecular mechanisms involved in the acquisition of the metastatic phenotype will be required to provide more effective therapeutic targets and prognostic markers of colon cancer progression.

Gene profiling has been used extensively to understand the genetic basis of metastasis. Several gene profiling studies on colon cancer metastasis have been published and these included comparisons of gene expression profiles between metastatic and primary tumors or tumors with and without lymph node metastasis (5). However, the overlaps in the candidate gene lists generated by these different studies are limited, due to the diverse types of patient samples used, different array platforms, data analysis algorithms and specific biases involved in each study. Moreover, recent studies have highlighted the heterogeneity in the cell population within a tumor sample. One of the mechanisms implicated in the progression to invasion and metastasis in colon tumors appears to involve primarily cells at the invasive front. The cells at the invasive fronts were shown to exhibit alterations in epithelial structure and function, leading to a dissolution of adherens junctions, reorganization of the actin cytoskeleton, loss of apical-basal polarity, loss of epithelial markers, induction of a mesenchymal gene-expression program and enhanced motility and invasion: a process referred to as epithelial-mesenchymal transition (EMT) (6-8). Hence, a global transcriptome analysis of whole tumor samples may obscure...
important genetic alterations that occur in the minority of cells within a tumor. An alternate strategy to identify genes associated with colon cancer metastasis, therefore, might be to compare gene expression profiles of cell lines with differing metastatic abilities. Studies have shown that nude mice may be used as ‘cell sorters’ to select for metastatic variants in xenograft models. This strategy was successfully used to identify genes that enhance lung metastasis by mouse melanoma cells (9), genes that promote metastasis to the bone in human breast cancers (10) and the transcription factor Twist in the promotion of EMT and metastasis in breast cancer cells (11).

To identify novel genetic changes important in colon cancer metastasis, we have characterized metastatic cell lines derived from a poorly metastatic human colon cancer cell line HCT116 using in vivo passaging in athymic nude mice. One of the metastatic cell lines, E1, exhibited features reminiscent of EMT with a mesenchymal/fibroblastic morphology, a loss of intercellular adhesion, increased invasiveness and increased metastatic potential compared to HCT116. The Erk signaling pathway, one of the important pathways involved in EMT (12) was also identified to be responsible for the EMT-like features of the E1 cells. However, the loss of intercellular adhesion in the E1 cells was not due to a reduction of E-cadherin expression. Instead, E-cadherin and components of the cadherin-catenin complex (β-catenin, α-catenin, α-actinin, p120-catenin) were localized to the cytoplasm of the cells rather than adherens junctions. Gene expression array analysis on the E1 cell line in comparison to the parental HCT116 showed dysregulation of gene expression in known metastasis mediators such as S100A4, EMT-related genes or genes involved in intestinal epithelium development pathways such as BMP4, Jag1 Sox9, genes affecting chromatin structure/ transcription that has been shown to promote metastasis such as SATB1 as well as genes affecting cytoskeletal organization or cell adhesion such as PDGFL5, PALLD (palladin), DLG5, DSC2, PLEC1, ITGA6. In this study, we have identified palladin, an actin cross-linker and scaffold for the formation of actin-associated protein complexes, as a novel regulator of EMT and metastasis in breast cancer cells (11).

Materials and methods

Cell culture and transfections. The human colon cancer cell line HCT116 was purchased from American Type Culture Collection (ATCC). The HCT116 cell line and its metastatic derivative E1 were cultured in McCoy’s 5A medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen™). Cells were grown as adherent cultures at 37°C in a humidified incubator supplemented with 5% CO₂. Palladin expression in HCT116 cells was silenced by transient transfection of Stealth™ RNAi targeted against palladin (Invitrogen) using Lipofectamine™ RNAiMAX reagent (Invitrogen). RNAi #1 (5’ gggcagcccttcaaatgcaatt caa 3’) and RNAi #4 (5’ gcctggtgaatgagcttatttca 3’) target the 140 kDa palladin isoform. RNAi #2 (5’ cagctgccgtg gtagctgttatttca 3’) and RNAi #3 (5’ gcctggtgaatgagcttatttca 3’) target both the 90 and 140 kDa palladin isoforms. Transfected cells were usually re-seeded for other functional assays 24 h post-transfection. Medium GC Duplex (Invitrogen) was used as a negative control as the RNAi synthesized were of medium GC content (i.e., 45-55% GC).

Cell aggregation assay. Adherent cells were detached by Cell Dissociation Buffer (Invitrogen) and dispersed by pipetting into single cell suspension. Ten thousand cells were added to each well of the 24-well ultra low cluster plates (Corning Costar) and cultured for 24 h in a tissue culture incubator, after which images were taken with a camera attached to the Zeiss Axiovert microscope equipped with a x10 phase-contrast objective. Three independent experiments were carried out in triplicates for each treatment condition.

In vitro invasion assay. BD Matrigel™ basement membrane matrix (BD Biosciences) was diluted 10-fold and coated on the upper chamber membrane (pore size 8.0 μm) in 6.5 mm diameter transwells (Corning Costar). Cells were harvested by trypsinization and plated on the upper chamber of each transwell at a density of 5x10⁵ cells/100 μl of serum-free McCoy’s 5A modified media. Complete McCoy’s 5A modified media was added to the lower chamber. The transwells were incubated at 37°C in a humidified incubator supplemented with 5% CO₂ for 48 h, after which the cells in the upper chamber were removed and the upper-side of the membrane thoroughly cleaned. Cells that have invaded through the Matrigel-coated membrane were stained with crystal violet. Three independent experiments were carried out in triplicates for each treatment condition.
Establishment and characterization of metastatic variants from HCT116 cell line. Five-week-old female athymic mice were purchased from Animal Resources Centre (Canning Vale, Australia) and maintained under specific pathogen-free conditions. The in vivo selection procedure used for the generation of metastatic variants from HCT116 colon cancer cell line has been described (18). Briefly, 2x10⁶ cells suspended in 0.05 ml of PBS was injected into the medial spleen tip. Six to eight weeks after injection, the animals were sacrificed and post-mortem examination performed. The hepatic metastatic nodules were obtained, washed in McCoy’s 5A modified medium containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin B, and minced. Following incubation with 50 U/ml dispase I for 30-60 min at 37˚C, the dispersed cells were filtered through a 100 μm filter. The cells obtained from the hepatic metastatic nodules at 37˚C, in PBS pH 7.4) were resolved on a 10% gel, transferred in PBS pH 7.4, 1% 2-mercaptoethanol, 50 mM Tris buffer pH 7.4, 1% SDS in PBS pH 7.4) were resolved on a 10% gel, transferred to nitrocellulose membrane (Hybond C-Extra, Amersham Biosciences) and probed for the expression of E-cadherin, ß-catenin, α-actinin, GAPDH (ß-catenin, p120-catenin). Polyclonal antibodies against palladin were purchased from Proteintech (ß-catenin, α-actinin, GAPDH) and BD Transduction Labs. (ß-catenin, α-actinin, p120-catenin). Polyclonal antibodies against palladin were purchased from Proteintech Group Inc., while those against total p44/42 MAP kinase (Erk1 and Erk2) and phospho-44/42 MAP kinase (Erk1 and Erk2) from Cell Signaling Technology. The method for co-immunoprecipitation has been described (14). The polyclonal anti-palladin antibody from Proteintech was used for immunoprecipitating palladin and its interacting proteins.

Flow cytometry (FACS). Cells were detached by incubation with 0.5 mM EDTA/PBS at 37˚C for 5 min. Cells were pre-incubated with 20% (v/v) goat serum (Dako Cytomation) for 20 min on ice, and then with the respective primary antibodies or isotype control antibodies diluted in FACSwash [2.5% (v/v) PBS in PBS] for 1 h on ice. Subsequently, the respective FITC-conjugated secondary antibodies were added and incubated for a further 30 min to 1 h. Flow cytometry was carried out using the FACScalibur (Becton-Dickinson Immunocytometry Systems). The data were analyzed using the WINMDI v2.8 software (Scripps Institute). The anti-α6 and anti-β4 integrin antibodies were from Chemicon International Inc.

Reverse transcription-PCR (RT-PCR). Cells were cultured to similar densities and RNA extracted using RNeasy Mini Kit (Qiagen). RT-PCR of specific genes were amplified with primers listed in Table I with cycle conditions of 94˚C for 30 sec, primer annealing temperature Tm for 30 sec, 72˚C for 30 sec, for 25-35 cycles.

Table I. RT-PCR primers.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer sequence (5’→3’)</th>
<th>Reverse primer sequence (5’→3’)</th>
<th>Primer annealing temperature used (˚C)</th>
<th>Size of PCR product (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANXA10</td>
<td>GGCCGGGACCTGATTGG</td>
<td>AGCAATGAGGTCCTCCGAT</td>
<td>56</td>
<td>208</td>
</tr>
<tr>
<td>BMP4</td>
<td>CTCGCCGTTCCCTGCT</td>
<td>TGGTTAGGCTAAGCTTGG</td>
<td>60</td>
<td>233</td>
</tr>
<tr>
<td>BTBD3</td>
<td>AGCAAGGTCTGCTGAGGG</td>
<td>GCACCGACTGAAAAGCT</td>
<td>56</td>
<td>219</td>
</tr>
<tr>
<td>DSC2</td>
<td>AAAAATGGTGGTTGTTGCTGCTAC</td>
<td>AAAATGAAATAATGGACAAGC</td>
<td>52</td>
<td>250</td>
</tr>
<tr>
<td>FN (fibronectin)</td>
<td>AAGAGGAGGAGCGAAGGTC</td>
<td>ACCTCATGAGGTCGATG</td>
<td>52</td>
<td>303</td>
</tr>
<tr>
<td>HOXC10</td>
<td>CCGAACATCTGGGAATCGCCT</td>
<td>ACCCTTCTTCCCTCCGCT</td>
<td>56</td>
<td>267</td>
</tr>
<tr>
<td>JAG1</td>
<td>GGACAGGTCTGCTGCTCT</td>
<td>GGCTCGAACAGCAGT</td>
<td>52</td>
<td>213</td>
</tr>
<tr>
<td>MMP9</td>
<td>CCGACCGAGCTGATC</td>
<td>ACGGTATCAAGGTCATCATG</td>
<td>54</td>
<td>286</td>
</tr>
<tr>
<td>MYO6</td>
<td>CATCGGCGCTCGCCGAC</td>
<td>GCACCAAGCTTGGAG</td>
<td>56</td>
<td>201</td>
</tr>
<tr>
<td>OCLN (occludin)</td>
<td>AAGGGAGGAGGCGAAGGTC</td>
<td>CTCAAACATGCTTGTGAGT</td>
<td>60</td>
<td>396</td>
</tr>
<tr>
<td>PALD</td>
<td>TGCTGTGAGAAGCGAAGGG</td>
<td>CCAATACACAGCATTTCC</td>
<td>52</td>
<td>225</td>
</tr>
<tr>
<td>PDLIM5</td>
<td>TGCCCAGGGACGGTCGAGC</td>
<td>GGCAGCAGCTGAGGTGC</td>
<td>58</td>
<td>288</td>
</tr>
<tr>
<td>RHOB</td>
<td>CCGAGGAGCAGCTAGGACG</td>
<td>CCGGCTTGTGGTCCGTG</td>
<td>58</td>
<td>312</td>
</tr>
<tr>
<td>S100A4</td>
<td>ACTGCTGTCATGGCGGT</td>
<td>CGTACACATGGCAGGTG</td>
<td>50</td>
<td>270</td>
</tr>
<tr>
<td>SOX9</td>
<td>CGAAGGCACTACAGAACGG</td>
<td>GCGGATGAGGAGAAGGACC</td>
<td>60</td>
<td>291</td>
</tr>
<tr>
<td>TMOD3</td>
<td>TCAGTCTTGGCGACCCACC</td>
<td>GTCGGTGGTCCCGTCTG</td>
<td>58</td>
<td>292</td>
</tr>
<tr>
<td>ZNF161</td>
<td>AGCCGAAGCTCCTGGATGCTCT</td>
<td>AGTACTGCGGTCTTCTCCTC</td>
<td>58</td>
<td>285</td>
</tr>
<tr>
<td>GAPDH</td>
<td>ATCTCTGCCCTCTGTGCTGA</td>
<td>GATGACCTTGCCACAGCCT</td>
<td>60</td>
<td>302</td>
</tr>
</tbody>
</table>

Western blot analysis and co-immunoprecipitation. Equal amounts of proteins extracted using lysis buffer (6 M urea, 1% 2-mercaptoethanol, 50 mM Tris buffer pH 7.4, 1% SDS in PBS pH 7.4) were resolved on a 10% gel, transferred to nitrocellulose membrane (Hybond C-Extra, Amersham Biosciences) and probed for the expression of E-cadherin, ß-catenin, α-actinin, p120-catenin, α-actinin and palladin. For the detection of phosphorylated Erk and total Erk expression, cells were lysed in extraction buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate) and used immediately. Expression of GAPDH was used as loading control in all experiments. Monoclonal antibodies (mAb) were obtained from Chemicon International Inc. (E-cadherin), Santa Cruz Biotechnology Inc. (ß-catenin, α-actinin, GAPDH) and BD Transduction Labs. (ß-catenin, p120-catenin). Polyclonal antibodies against palladin and its interacting proteins.

Flow cytometry (FACS). Cells were detached by incubation with 0.5 mM EDTA/PBS at 37˚C for 5 min. Cells were pre-incubated with 20% (v/v) goat serum (Dako Cytomation) for 20 min on ice, and then with the respective primary antibodies or isotype control antibodies diluted in FACSwash [2.5% (v/v) PBS in PBS] for 1 h on ice. Subsequently, the respective FITC-conjugated secondary antibodies were added and incubated for a further 30 min to 1 h. Flow cytometry was carried out using the FACScalibur (Becton-Dickinson Immunocytometry Systems). The data were analyzed using the WINMDI v2.8 software (Scripps Institute). The anti-α6 and anti-β4 integrin antibodies were from Chemicon International Inc.
Microarray data collection and analysis. Microarray analysis was performed on the HCT116 cell line and its 7 metastatic derivatives using Affymetrix HGU133A chips (Affymetrix Inc.). RNA extracted from the cell lines were processed according to the protocol outlined in the Affymetrix technical manual. Three independent biological replicates were profiled for each of the cell lines. MicroArray Suite 5.0 (MAS) (Affymetrix Inc.) was used for the initial analysis of the scanned images. For absolute analysis, each chip (n=5) was scaled to a target intensity of 500 and probe sets were assigned a signal intensity and detection call of ‘Present, Marginal or Absent’. The absolute data (signal intensity, detection call and detection p-value) were exported into GeneSpring v7.2 software (Silicon Genetics) for further analysis by parametric test based on the crossgene error model (PCGEM). Firstly, all of the measurements on each chip were divided by the 50th percentile value (per chip normalization). Secondly, each gene was normalized to the baseline value of the control samples (per gene normalization) using the mean. Genes from ‘all genes’ with expression control signal greater than 20 in at least 45% of the conditions were selected. Genes ‘Present’ or ‘Marginal’ in at least 18% of the samples were then selected. Subsequently, the genes were filtered on a fold change of 2 or greater against controls (values obtained for HCT116 cell line) in at least one of the 7 metastatic cell lines studied. ANOVA was used to identify differentially expressed genes (p<0.05) and the Bonferroni multiple testing correction was applied to determine statistical significance. Finally, data representing replicates of the same experimental condition were averaged. For this study, further selection from the above list was carried out for genes demonstrating at least a 2-fold change in E1 compared to HCT116. A total of 93 unique genes (114 probe sets), of which 43 are up-regulated and 50 are down-regulated, met these criteria. The differentially expressed genes were annotated according to the Gene Ontology-Biological process (http://www.geneontology.org) and further clustered using the GeneSpring v7.2 software.

Wound healing assay. Cells were seeded in 6-well plates and grown for 24 h to confluency. A pipette tip was drawn carefully through the monolayer to create a wound between cells. To study the morphology and the migration pattern of the cells at the wound front, still images (×20 magnification) were captured at 24 h post-wounding. For live-imaging of cell movements during the wound healing process, the cells were treated as above, then transferred to a heated stage attached to the Olympus Fluoview FV1000 microscope. The conditions were maintained at 37°C, 5% CO₂ and with a water reservoir to maintain humidity. The field of view was centered over a section of the wound front and phase images captured for the next 18 h (at 1 frame/5 min) using time-lapse microscopy. Images were saved as ‘compressed AVI Files’, using the Olympus Fluoview 1.3 software, to generate the video.

Immunohistochemistry. Eighteen matched tissue samples of normal colonic mucosa, tumor and liver metastases were obtained from the National University of Singapore (NUS), Department of Pathology. Informed patient consent was obtained for all of the cases. The use of the tissue samples for this project was approved by the NUS Institutional Review Board. Immunohistochemical analysis was performed using a standard indirect immunoperoxidase method. Thick sections (4 µm) of formalin-fixed, paraffin-embedded tissues were deparaffinized, underwent antigen retrieval at 95°C for 10 min using Tris-buffered solution at pH 9.0 (Dako) followed by treatment with hydrogen peroxide for 5 min. Rabbit polyclonal antibody against palladin (Proteintech) was used at a dilution of 1:1000, with overnight incubation at room temperature. This was followed by the usage of a non-avidin-biotin polymer-based detection method (Envision+, Dako). Hematoxylin was used as counterstain. The 18 matched samples were treated under similar conditions of fixation, embedding and storage. Palladin expression in muscle cells was considered the appropriate internal control to assess the adequacy of the procedure. Images were taken using a Nikon ECLIPSE 90i microscope.

Results

The E1 cell line, a metastatic variant derived from poorly metastatic HCT116 human colon cancer cell line, has an EMT-like phenotype and is more invasive. Metastatic cell lines were derived from the poorly metastatic human colon cancer cell line HCT116 by serial transplantation in athymic nude mice, according to a well-established model for metastatic colorectal cancer (18). Briefly, the HCT116 cells were injected into the sub-capsular region of the spleen and the resulting metastatic nodules in the liver were harvested and expanded into derivative cell lines. Clonal lines including E1 were derived from the liver metastatic tumor nodules by means of limiting dilution. Histopathology of the tumors in the liver and spleen of the nude mice showed adenocarcinoma confirming that the tumors were derived from the cells injected (data not shown). Karyotype analysis using mFISH and qFISH techniques showed that all the derivative cell lines displayed similar non-reciprocal translocations (t8,16; t16,10; t17,18) as those found in the parental HCT116 cell line (data not shown).

Monolayer cultures of the derived cell lines showed similar epithelial morphology compared to the HCT116 cell line in phase-contrast microscopy, except that of the E1 cell line. The E1 cell line exhibited a mesenchymal/fibroblastoid spindle-shaped morphology, loss of contact inhibition of growth and reduced intercellular contacts even at high density, when compared to the parental HCT116 cells (Fig. 1A). When cultured as suspension cultures in low cluster plates, HCT116
Figure 1. The morphology, invasiveness and metastatic potential of HCT116 and E1 cells. A, Phase-contrast microscopy showing the morphology of HCT116 and E1 cells cultured at low (left panel) and high densities (right panel). B, Suspension cultures of HCT116 and E1 cells in low cluster plates. C, In vitro invasion assays were carried out for the HCT116 and E1 cell lines. Crystal violet staining of cells that have invaded through the Matrigel-coated 8 μm pore-size membranes of Transwell® chambers is shown. The images are representative of 3 independent experiments carried out in triplicates for each respective cell line. D, Mice were injected intrasplenically with 1x10⁶ cells and sacrificed after 6-8 weeks, at which time the number of liver metastases nodules was determined. Shown are pictures of the spleen and liver obtained from mice injected with the respective HCT116 and E1 cell lines. Arrows indicate splenic tumor and liver metastatic nodules. The number of mice, injected with the respective HCT116 and E1 cells, that developed liver metastases was tabulated.
The loss of intercellular adhesion in E1 cells is associated with a cytoplasmic localization of E-cadherin. Besides a change in gross morphology and the loss of intercellular adhesion, EMT is also characterized by changes in the expression of various epithelial and mesenchymal proteins, as well as cytoskeleton reorganization. Actin organization in the HCT116 and E1 cell lines was studied using staining the actin cytoskeleton with phalloidin and visualization with confocal microscopy. HCT116 cells exhibited numerous spike-like filopodia and stress fibres at the cortical surface. In contrast, the E1 cell line, showed reduced filopodia and cortical stress fibres, with more prominent lamellipodia (Fig. 2A). As filopodia formation is a feature of epithelial cell movement, which occurs in events such as epithelial sheet closure during development (19), reduced filopodia formation in E1 cells suggests that these cells have acquired a mesenchymal/fibroblast-like phenotype.

We also investigated the mesenchymal transformation in the E1 cells by determining the expression of a number of well-characterized epithelial and mesenchymal markers. Although the loss of E-cadherin (epithelial marker) expression leading to the disruption of E-cadherin-dependent junctions is one of the hallmarks of EMT (6,20), we did not detect a loss of E-cadherin expression in the E1 cells (Fig. 2B). However, dissolution of the adherens junction was associated with a cytoplasmic localization of E-cadherin in E1 cells, indicative of a mesenchymal phenotype (21), compared to its localization at the intercellular junction in HCT116 cells (Fig. 2A). Cytoplasmic localization, without a loss in protein expression (Fig. 2B), was also observed for other proteins in the E-cadherin-catenin complex (i.e. β-catenin, α-catenin, α-actinin, p120-catenin) in E1 cells, indicating that the E-cadherin-catenin complex may be disrupted without necessarily losing the expression of any of its components. These proteins exhibited adherens junction localization in HCT116 cells (Fig. 2A).

The E1 cells showed a down-regulation in expression of other epithelial or polarity markers, such as integrin α6β4 (Fig. 2C), the tight junction protein occludin (Fig. 2D) and the desmosome protein desmocollin DSC2 (Fig. 2D) (12,22,23). Other mesenchymal markers such as fibroblast-specific protein-1 (FSP-1/S100A4), fibronectin (Fn) and matrix metallopeptidase 9 (MMP9) were up-regulated in E1 compared to HCT116 cells (Fig. 2D). However, vimentin, another mesenchymal marker, was not detected in E1 cells using either Western blot analysis or RT-PCR (data not shown). The loss/gain in expression of some epithelial/mesenchymal markers, without a change in expression of E-cadherin and vimentin, indicate that there are additional mechanisms involved in the disruption of E-cadherin-dependent junctions and mesenchymal transformation in E1 cells apart from suppression of E-cadherin and vimentin expression. In fact, there are many examples where advanced metastatic carcinoma cells adopt only a subset of mesenchymal features and retain the characteristics of well-differentiated epithelial cells or exhibit an absence of the end-point defining characteristics of EMT. For example, carcinoma cells may exhibit a metastatic and mesenchymal-like phenotype but do not show a reduction in E-cadherin expression (24-28). This has led to the concept of ‘incomplete EMT’ (29) and metastatic cells possessing both epithelial and mesenchymal features (28). Hence, it appears that EMT does not constitute a single ‘on-off’, end-point defined process, but rather, is a continuum of change towards a mesenchymal phenotype (22).

Therefore, this loss/gain in expression of some epithelial/ mesenchymal molecular markers, cytoskeleton reorganization, together with the data on the loss of intercellular adhesion, an elongated cell shape and increased invasiveness and metastatic potential, is consistent with a mesenchymal change in the E1 cells.

Genes involved in intestinal epithelium development and cytoskeleton organization are amongst those that are differentially regulated in the E1 cells. To identify novel genes associated with metastasis and invasiveness, transcriptomic microarray analysis was carried out on the HCT116 cell line and the E1 metastatic cell line derived from it. The gene list obtained from the comparison of E1 versus HCT116 was filtered to exclude very low expression signals. Genes demonstrating at least 2-fold change in E1 compared to HCT116 were subjected to statistical analysis to determine significance at p<0.05 (two-way ANOVA followed by Bonferroni multiple testing correction). A total of 93 unique genes (114 probe sets), of which 43 are up-regulated and 50 are down-regulated, met these criteria. Fig. 3A shows a list of the genes classified based on Gene Ontology Biological Processes (GO BP). Of these, S100A4 has been shown to be an important metastasis mediator (30). PLEC1 is a potential metastasis suppressor gene (31,32), whilst the up-regulation of Jag1, Sox4, HMGAl, SEMA3A, CD24 has been associated with metastasis and/or invasiveness, with CD24 being a prognostic marker in the metastatic progression of colon cancer (33). Up-regulation of SATB1, which reprogrammes chromatin organization, has been presented as a new mechanism of tumour progression and metastasis in a recent publication (34). Four of the up-regulated genes, BMP4,
Figure 2. Expression and localization of epithelial and mesenchymal markers in HCT116 and E1 cells. A, Confocal microscopy images of HCT116 and E1 cells fluorescently stained with respective antibodies against E-cadherin, β-catenin, α-catenin, p120-catenin, α-actinin and phalloidin. B, Western blot analysis on the expression of E-cadherin, β-catenin, α-catenin, p120-catenin and α-actinin in HCT116 and E1 cells cultured to similar density (~80% confluent). GAPDH was used as a loading control. C, FACS analysis detecting for surface expression of integrins α6 and β4 in HCT116 and E1 cells. Open profiles are signals detected using the integrin antibodies, shaded profiles are signals detected using isotype control antibody. D, mRNA expression of epithelial/polarity markers (desmosome, occludin) and mesenchymal markers (S100A4, fibronectin, MMP9) was studied by RT-PCR using RNA extracted from HCT116 and E1 cells cultured to a similar density (~80% confluent). GAPDH was used as a loading control.
Jag1, S100A4 and Sox9, are also known to induce EMT during cancer progression and/or development (35-39).

Interestingly, several of the dysregulated genes are involved in signaling pathways that are important for intestinal epithelium development and intestinal stem cell maintenance: i) BMP4, CCND1, Met, Jag1, Sox9, Sox4 are known target
genes of the Wnt/β-catenin signaling pathway (obtained from Roel Nusse’s recent work on colorectal cancer, http://www.stanford.edu/~rnusse/wntwindow.html), ii) BMP4, FUT8, Smad3 and PEG10 belong to the TGFβ/BMP signaling pathway, iii) Jag1 is a ligand for the Notch pathway. The dysregulation of genes in pathways involved in intestinal development further validates the relevance of the gene list for colon cancer metastasis. Another potentially interesting and important set of genes identified are those involved in cytoskeleton organization/actin binding and cell adhesion. Many of these, e.g., PDLIM5, ABLIM1, palladin, DLG5, have domains such as PDZ, LIM, Ig, ZnF, proline-rich, actin binding domains that allow for protein-protein interactions and could act as scaffolds for formation of multiprotein complexes (13,40-43). These proteins could mediate interactions between actin filaments/cytoskeleton and cytoplasmic targets, functioning in the transmission of extracellular signals to the cytoskeleton. The functions of this set of genes may explain the morphological changes observed in the transition of epithelial HCT116 to the more mesenchymal, metastatic E1 cells. For example, the loss of PLEC1 and ITGA6, both components of hemidesmosomes (44,45), might result in the disruption of hemidesmosomes and hence the detachment of a tumor cell from the basement membrane prior to its migration away from the tumor mass. DSC2, found primarily in epithelial cells and required for cell adhesion, desmosome formation (23), was down-regulated in the mesenchymal E1 cells. The actin filament pointed-end capping

Figure 4. Effects of palladin knockdown on intercellular adhesion, collective migration and localization. A, Western blot analysis of palladin expression in HCT116 and E1 cells, HCT116 cells transfected with control RNAi (GCtl), RNAi #1, #2, #3 or #4. RNAi #1 and #4 were designed to knockdown only the 140 kDa palladin isoform, RNAi #2 and #3 were designed to knockdown both the 90 and 140 kDa palladin isoforms. GAPDH was used as a loading control. HCT116 and E1 cells were cultured to a similar density (~80%) before protein extraction. Transfected cells were harvested for protein extraction at 48 h post-transfection. Similar profiles were obtained with cells harvested at 24, 72 and 96 h post-transfection (data not shown). B, Suspension cultures of HCT116 and E1 cells, HCT116 cells transfected with control RNAi (GCtl), RNAi #1, #2, #3 or #4. RNAi-transfected HCT116 cells were re-seeded into the low cluster plates at 24 h post-transfection. Cells were cultured in suspension for 24 h in the tissue culture incubator, after which images were taken with a camera attached to the Zeiss Axiovert microscope equipped with a x10 phase-contrast objective. C, Still images of the wound fronts of untransfected HCT116, E1 cells and HCT116 cells transfected with control RNAi (GCtl), RNAi #1, #2, #3 or #4. RNAi-transfected HCT116 cells were re-seeded for the wound healing assay at 24 h post-transfection. Cells were seeded at the appropriate density such that they were 100% confluent after 24 h culture, upon which the monolayer was artificially wounded by scratching with a pipette tip. These images were captured at 24 h post-wounding.
Figure 5. Effects of palladin knockdown on the expression and localization of palladin. A, Confocal microscopy images of HCT116 and E1 cells fluorescently stained with anti-palladin antibody. Two focal planes were captured for HCT116 cells: 1, plane 1 shows palladin staining at the focal adhesions, spike-like filopodia structures and 2, plane 2 shows the staining at adherens junction. B, Confocal microscopy images of HCT116 cells constained with anti-palladin antibody and either anti-E-cadherin antibody (upper panel) or anti-α-actinin antibody (lower panel). C, Immunoprecipitates from the cell lysate using anti-palladin antibody were probed with anti-α-actinin antibody, which indicated that α-actinin co-precipitated with palladin in HCT116 cells (upper panel). Samples of whole cell lysate were run as input control (lower panel). E1 sample that contained minimal palladin was run as a negative control. D, Confocal microscopy images of HCT116 cells transfected with control RNAi (GCctl) or RNAi #2, co-stained with anti-palladin and anti-E-cadherin antibodies. Staining was carried out on transfected cells at 24 h post-transfection.
Figure 5. Continued. E, Protein extracts of HCT116, E1 cells and HCT116 cells transfected with control RNAi (GCctl) or RNAi #2 (at 24 h post-transfection) were probed for palladin and E-cadherin. There was an almost complete knockdown in palladin expression in HCT RNAi #2 cells, without any changes in E-cadherin expression.

Knockdown of palladin results in a reduction in intercellular adhesion and collective migration. Amongst the genes that were differentially regulated in E1 in comparison to HCT116 cells is palladin, an actin cross-linking protein that also acts as a scaffold for multiple actin-binding proteins, such as α-actinin, VASP, profilin, ezrin and Eps8 (13). In the present study, we focused on examining whether the down-regulation of palladin contributed to the morphological changes as well as the loss of the intercellular adhesion observed in E1 cells. Palladin mRNA expression was confirmed to be down-regulated in E1 cells compared to HCT116 cells (Fig. 3B). Two isoforms of palladin were detected in HCT116 cells, a more abundant E1 cells compared to HCT116 cells (Fig. 3B).

The changes in mRNA expression of S100A4, DSC2 (Fig. 2D), ANXA10, BTBD3, BMP4, HOXC10, Jag1, MYO6, Palladin, PDLIM5, Rhob, Sos9, TMOD3, Znf161 observed in the microarray data were independently validated by RT-PCR (Fig. 3B).

The effect of palladin down-regulation on intercellular adhesion was analyzed using a cell aggregation assay. Knockdown of both palladin isoforms resulted in a reduction of intercellular adhesion. HCT116 cells transfected with either RNAi #2 or #3 (HCT RNAi #2, HCT RNAi #3) targeted against both isoforms aggregated loosely as a suspension of small clusters, unlike their control RNAi-transfected counterparts (HCT GCctl) which still formed large aggregates or spheroids (Fig. 4B), resembling that of E1 cells. HCT116 cells transfected with RNAi #1 or #4 (HCT RNAi #1, HCT RNAi #4) targeted only against the 140 kDa isoform formed large spheroids, resembling that of untransfected HCT116 cells and HCT GCctl cells (Fig. 4B), indicating that the loss of the 140 kDa isoform alone is insufficient to cause a reduction in intercellular adhesion.

The effect of the loss of intercellular adhesion (an EMT feature) on cell motility was examined using wound healing assays. Cells cultured to confluence were artificially wounded by scratching a pipette tip across the monolayer and analyzed for up to 24 h. The wound fronts of HCT116 cells treated with RNAi targeted to both palladin isoforms (RNAi #2 and HCT RNAi #3) resembled that of E1 cells, having a spindle-shaped/mesenchymal morphology with a reduction in intercellular adhesion and contact inhibition. Single cells extending out of the wound front were also observed (Fig. 4C). This contrasted with the wound fronts of HCT116 treated with RNAi specifically targeted towards the 140 kDa isoform (HCT RNAi #1), as well as HCT116 treated with control RNAi (HCT GCctl) and untransfected HCT116, which exhibited epithelial morphology with preservation of intercellular adhesion (Fig. 4C). Cell movements during the wound healing process of E1, HCT GCctl and HCT RNAi #2 cells were also captured for 18 h using time-lapse microscopy. HCT GCctl cells exhibited directional, collective migration as an epithelial sheet with intercellular adhesion. Cells remained attached throughout, with none detaching to migrate independently (data not shown). This organized cell sheet migration was absent in E1 cells. Instead, the spindle-shaped elongated cells moved independently of their neighbours rather than as a cohesive unit. Individual cells were also observed to extend out of the wound-front (data not shown). HCT RNAi #2 cells exhibited a loss of organized cell sheet migration and intercellular adhesion, with individual cells moving away from the wound front, resembling the migration pattern of E1 cells. Knockdown of both the palladin isoforms also resulted in cells that have a spindle-like morphology, although these cells were not as elongated as the E1 cells (data not shown). The rate of wound healing (i.e., rate of cell motility) was also calculated by measuring the distances of the wound covered by the respective cells at the end of 24 h (using the still images captured at 0 and 24 h).

Amongst the genes that were differentially regulated in E1 in comparison to HCT116 cells is palladin, an actin cross-linking protein that also acts as a scaffold for multiple actin-binding proteins, such as α-actinin, VASP, profilin, ezrin and Eps8 (13). In the present study, we focused on examining whether the down-regulation of palladin contributed to the morphological changes as well as the loss of the intercellular adhesion observed in E1 cells. Palladin mRNA expression was confirmed to be down-regulated in E1 cells compared to HCT116 cells (Fig. 3B). Two isoforms of palladin were detected in HCT116 cells, a more abundant E1 cells compared to HCT116 cells (Fig. 3B).

The changes in mRNA expression of S100A4, DSC2 (Fig. 2D), ANXA10, BTBD3, BMP4, HOXC10, Jag1, MYO6, Palladin, PDLIM5, Rhob, Sos9, TMOD3, Znf161 observed in the microarray data were independently validated by RT-PCR (Fig. 3B).

The effect of palladin down-regulation on intercellular adhesion was analyzed using a cell aggregation assay. Knockdown of both palladin isoforms resulted in a reduction of intercellular adhesion. HCT116 cells transfected with either RNAi #2 or #3 (HCT RNAi #2, HCT RNAi #3) targeted against both isoforms aggregated loosely as a suspension of small clusters, unlike their control RNAi-transfected counterparts (HCT GCctl) which still formed large aggregates or spheroids (Fig. 4B), resembling that of E1 cells. HCT116 cells transfected with RNAi #1 or #4 (HCT RNAi #1, HCT RNAi #4) targeted only against the 140 kDa isoform formed large spheroids, resembling that of untransfected HCT116 cells and HCT GCctl cells (Fig. 4B), indicating that the loss of the 140 kDa isoform alone is insufficient to cause a reduction in intercellular adhesion.

The effect of the loss of intercellular adhesion (an EMT feature) on cell motility was examined using wound healing assays. Cells cultured to confluence were artificially wounded by scratching a pipette tip across the monolayer and analyzed for up to 24 h. The wound fronts of HCT116 cells treated with RNAi targeted to both palladin isoforms (RNAi #2 and HCT RNAi #3) resembled that of E1 cells, having a spindle-shaped/mesenchymal morphology with a reduction in intercellular adhesion and contact inhibition. Single cells extending out of the wound front were also observed (Fig. 4C). This contrasted with the wound fronts of HCT116 treated with RNAi specifically targeted towards the 140 kDa isoform (HCT RNAi #1), as well as HCT116 treated with control RNAi (HCT GCctl) and untransfected HCT116, which exhibited epithelial morphology with preservation of intercellular adhesion (Fig. 4C). Cell movements during the wound healing process of E1, HCT GCctl and HCT RNAi #2 cells were also captured for 18 h using time-lapse microscopy. HCT GCctl cells exhibited directional, collective migration as an epithelial sheet with intercellular adhesion. Cells remained attached throughout, with none detaching to migrate independently (data not shown). This organized cell sheet migration was absent in E1 cells. Instead, the spindle-shaped elongated cells moved independently of their neighbours rather than as a cohesive unit. Individual cells were also observed to extend out of the wound-front (data not shown). HCT RNAi #2 cells exhibited a loss of organized cell sheet migration and intercellular adhesion, with individual cells moving away from the wound front, resembling the migration pattern of E1 cells. Knockdown of both the palladin isoforms also resulted in cells that have a spindle-like morphology, although these cells were not as elongated as the E1 cells (data not shown). The rate of wound healing (i.e., rate of cell motility) was also calculated by measuring the distances of the wound covered by the respective cells at the end of 24 h (using the still images captured at 0 and 24 h).
Figure 6. Effects of the inhibition of the Mek/Erk pathway on the morphology of E1 cells and the expression and localization of palladin. A, Phase-contrast microscopy showing the morphology of: HCT116 cells, untreated E1 cells, or E1 cells treated with DMSO (control), 10, 25 or 50 μM of U0126. B, Suspension cultures of: E1 cells treated with DMSO or 25 μM of U0126 (top panel); E1 cells transfected with control RNAi (middle panel) or RNAi #2 (bottom panel), followed by treatment with DMSO (left column) or 25 μM of U0126 (right column). All cells were treated with DMSO or U0126 for 24 h before re-seeding into low cluster plates. Cells were cultured in suspension for 24 h in the tissue culture incubator, after which images were taken with a camera attached to the Zeiss Axiovert microscope equipped with a x10 phase-contrast objective. C, Palladin mRNA and protein expression in untreated E1 cells, E1 cells treated with DMSO or U0126 for 24 h was studied using RT-PCR (a) and Western blot analysis (b), respectively. The expression of phosphorylated Erk (pErk) and total Erk in untreated E1 cells and E1 cells treated with DMSO or U0126 for 24 h was studied by Western blot analysis (b). Erk inhibition changed levels of pErk but not total Erk. GAPDH was used as a loading control. D, Confocal microscopy images of HCT116 cells, E1 cells treated with DMSO or 25 μM U0126 for 24 h, fluorescently stained with palladin and E-cadherin antibodies.
However, there were no significant changes in the rate of wound healing between the HCT116 cells and HCT116 cells transfected with respective RNAi (data not shown).

Thus, whilst a knockdown of both palladin isoforms in HCT116 cells did not significantly increase the rate of wound healing, a distinct change in the cell motility pattern was observed. The organized epithelial cell sheet migration in palladin knockdown cells was lost and there was also a reduction/loss of intercellular adhesion. The dysregulation of these two important features of EMT suggests that palladin has a role in EMT in the transformation of HCT116 cells to E1 cells.

Knockdown of palladin suppresses the junctional localization of E-cadherin without a change in total E-cadherin expression. The expression and localization of palladin were studied in HCT116 and E1 cells by immunofluorescence confocal microscopy. Palladin was localized to focal adhesions and spike-like filopodia structures (Fig. 5A, plane 1) and enriched at adherens junctions in HCT116 cells (Fig. 5A, plane 2). E1 cells showed a general reduction in staining with non-specific localization of palladin (Fig. 5A). Moreover, co-immunofluorescence staining showed a partial co-localization between palladin and adherens junction proteins (e.g., E-cadherin and α-actinin) in HCT116 cells (Fig. 5B). Co-immunoprecipitation analysis further confirmed a physical association between palladin and α-actinin in HCT116 cells (Fig. 5C), consistent with observations in other cell lines (47). No physical interaction between palladin and other major adherens junction proteins (E-cadherin, α-catenin, β-catenin and p120-catenin) was found in HCT116 cells using the co-immunoprecipitation assay (data not shown). These observations together suggest that palladin might physically associate with adherens junction protein complex via α-actinin in HCT116 cells.

As the knockdown of palladin affected the intercellular adhesion in HCT116 cells, we examined the effects of palladin down-regulation on E-cadherin localization and expression. The pattern of palladin and E-cadherin expression was unchanged in cells transfected with the control RNAi (HCT GCctl). Palladin was enriched at the adherens junctions, partially co-localized with E-cadherin and showed a more punctuate staining pattern compared to the more continuous staining pattern of E-cadherin (Fig. 5D). On the other hand, cells transfected with palladin RNAi #2 (HCT RNAi #2) exhibited diminished palladin staining associated with a decrease in E-cadherin localization at the adherens junctions. E-cadherin was localized to the cytoplasm/nucleus of these cells (Fig. 5D). The loss of palladin expression in the HCT RNAi #2 cells did not affect total E-cadherin expression (Fig. 5E), but changed its localization. Thus, we have established a novel link between palladin expression and the adherens junction protein complex in HCT116 cells whereby, a down-regulation of palladin caused a loss of junctional E-cadherin localization without a loss of E-cadherin expression.

The expression and localization of palladin to the adherens junction can be restored by inhibition of the Mek/Erk pathway. Multiple signaling pathways and effectors contribute to EMT. The TGFβ pathway and the Erk pathway downstream of receptor tyrosine kinases are examples of common signaling pathways involved in EMT (12). E1 cells treated with U0126, a chemical inhibitor of the Mek/Erk pathway, exhibited a reversion of its mesenchymal phenotype to an epithelial morphology resembling parental HCT116 cells (Fig. 6A). This was associated with a restitution of intercellular adhesion. E1
cells treated with 25 μM of U0126 (E1 U0126) formed large spheroids that were similar to those formed by the HCT116 cells (Fig. 4B) whereas DMSO treated cells retained a scattered single cell/small aggregation morphology (Fig. 6B) like that of untreated E1 (Fig. 4B). Associated with the changes in cell morphology and aggregation patterns, the inhibition of the Erk pathway in E1 cells caused an increase in palladin mRNA (RT-PCR) and the 90 kDa palladin isoform protein (Western blot analysis) expression (Fig. 6C). The palladin protein was correctly localized to adherens junctions as shown in the bottom panel of Fig. 6D. The staining patterns of both palladin and E-cadherin are indistinguishable between HCT116 cells and E1 cells treated with U0126.

To determine whether the reversion of E1 cells to an epithelial phenotype after U0126 treatment was dependent on palladin, we transfected E1 cells with control RNAi, palladin RNAi #2, #3 or #4 (E1 GCctl, E1 RNAi #2, E1 RNAi #3, E1 RNAi #4, respectively), before treating them with 10 or 25 μM U0126. The efficacy of preventing the up-regulation of palladin after U0126 treatment is shown in Fig. 6E. E1 cells transfected with control RNAi or RNAi #4 (which knocks down only the 140 kDa isoform) responded to U0126 treatment with a reversion of mesenchymal morphology to an epithelial morphology. However, cells transfected with either RNAi #2 or #3 did not respond to U0126 treatment and remained mesenchymal (Fig. 6F). Similarly, the reversion of the E1 cells to a more aggregated morphology after U0126 treatment was also prevented by prior treatment of the cells with RNAi #2 but not the control RNAi (Fig. 6B). These results indicate that the morphological changes associated with U0126 treatment are dependent on the induction of the 90 kDa palladin isoform and suggests that palladin is an integral component in the Erk signaling pathway regulating EMT in these cells.

**Palladin is strongly expressed at the adherens junctions and cytoplasm in well-differentiated tumor tubules and down-regulated in poorly-differentiated tumor tubules and dissociated tumor cells.** Immunohistochemical analysis of palladin expression was carried out on formalin-fixed paraffin-embedded tissues of 18 matched normal colonic mucosa and colorectal tumors obtained from the National University of Singapore, Department of Pathology. Most of the adenocarcinomas were classified as having a moderately differentiated phenotype, except for 3 cases which were moderately to poorly-differentiated. Palladin was expressed at the adherens junctions and cytoplasm of normal colonic epithelia. Expression was stronger at the well-differentiated surface epithelium (Fig. 7A, middle panel) compared to cells at the crypt (Fig. 7A, right panel). Although the tumor samples were broadly classified as moderately or poorly-differentiated, there was a heterogeneous mix of well to poorly-differentiated tubular areas within a sample. Interestingly, palladin expression appeared to be directly correlated to tubular differentiation. The better differentiated tubular structures showed stronger palladin staining that was localized to both adherens junctions and the cytoplasm (Fig. 7B, panels a, b), similar in pattern to that observed in adjacent normal mucosa (Fig. 7B, panel c). Palladin expression was down-regulated in tubules at the invasive front (Fig. 7B, panel d) where expression was predominantly cytoplasmic, with reduced or absent adherens junction expression (Fig. 7B, panels e, f). Palladin expression was most down-regulated in cell clusters and individual cells that have dissociated from the tumor tubules at the invasive front (Fig. 7C, panels a-d). Hence, the overall pattern of palladin expression appears to be correlated to tubular differentiation within the tumor sample. The better differentiated, intact tubules expressed higher levels of palladin, which is often localized at the adherens junctions and cytoplasm. Poorly-differentiated tubules and detached cell clusters and individual cells expressed low levels of palladin which is localized to the cytoplasm rather than adherens junctions. The pattern of expression and localization of palladin in primary tumors and adjacent normal tissue is consistent with its role in intercellular adhesion. The loss of palladin may be associated with the dedifferentiation of cells to a more mesenchymal phenotype and a necessary step to facilitate tumor invasion into surrounding tissues.

**Discussion**

Palladin is an actin cross-linking protein that also acts as a scaffold for multiple actin-binding proteins such as ezrin, VASP/Mena/EVL, profilin, α-actinin, Lasp-1 and Eps8 (15,16, 47-50) and signaling proteins such as ArgBP-2, SPIN-90 and Src (51,52). Palladin is commonly localized along stress fibers, dorsal ruffles and podosomes (14,48) where it is required in the assembly and maintenance of actin-dependent structures. Erk pathway in E1 cells caused an increase in the 90 kDa palladin isoform protein (Western blot analysis) expression (Fig. 6C). The palladin protein was correctly localized to adherens junctions as shown in the bottom panel of Fig. 6D. The staining patterns of both palladin and E-cadherin are indistinguishable between HCT116 cells and E1 cells treated with U0126.

Although there is an earlier study showing palladin localization at adherens junctions of chick pigmented epithelium (14), most of the studies on palladin have focused on its role in cell organization and cell motility rather than on intercellular adhesion. Our results establish a novel link between palladin expression and E-cadherin localization at adherens junctions in HCT116 cells. It appears that palladin is required for the proper localization of E-cadherin to adherens junctions and hence, the establishment and stabilization of these intercellular junctions amongst HCT116 cells. This is an important function, especially in the context of tumor progression, because a loss of E-cadherin on the cell surface has been shown to play a role in tumor progression and metastasis (23). Our data show that disruption of cell adherens junctions in HCT116 cells is not necessarily due to a loss of E-cadherin expression but may be caused by a loss of E-cadherin localization to the cell junctions. E-cadherin interacts with other key cytoskeletal components such as actin, α-actinin, vinculin and α-catenin at the junctions. A disruption of these interactions may lead to a destabilization of adherens junctions and a cytoplasmic rather than junctional localization of E-cadherin. For example, a reduced expression of α-catenin (which mediates connection of the E-cadherin/catenin complex to...
Figure 7. Immunohistochemical analysis of palladin expression in matched normal colonic mucosa and colorectal tumors tissue sections. A, Immunohistochemical staining of palladin in the surface epithelium and crypt of normal colonic mucosa (left panel) (x100 magnification). A further magnified section of the surface epithelium (middle panel) (x400), and the crypt (right panel) (x400). B, Colorectal tumor section showing palladin staining at the central tumor area (a) and at the invasive front (d). The central tumor area has intact well-differentiated tubules, (b) (x400) shows the magnified section of the boxed region in (a) (x100). The palladin staining in central tumor area was compared to that of matched normal colonic mucosa (c) (x400). Region of the invasive front was shown in (d) (x40). The circled and boxed regions showed the moderately-/poorly-differentiated tumor tubules, which are respectively enlarged in (e) (x400) and (f) (x400). Cells that have dissociated from the tumor tubules at the invasive front are indicated by the arrow and boxed region in (d) and shown enlarged in C(a) (x200) and (b) (x200), respectively. C, Representative examples of palladin expression of de-differentiated tumor areas (indicated by arrows) in the invasive fronts of colorectal tumor sections, which could exhibit as dissociated cells that form small clusters (a), (b), (c) (x200), or isolated tumor cells (d) (x400). Brown staining indicates positive palladin staining, blue hematoxylin was used as the counterstain.
actin cytoskeleton), has been frequently reported in colorectal cancers and may result in the cytoplasmatic relocation of E-cadherin (56). How a loss of palladin expression leads to the disruption of adherens junctions in HCT116 cells is unclear. Since we have validated that palladin can interact directly with α-actinin in HCT116 cells, one possibility is that palladin is required for the stabilization of the adherens junction protein complex to the actin cytoskeleton. α-actinin links the E-cadherin-catenin complex to the actin cytoskeleton through its interaction with α-catenin (57). It is possible that α-actinin might require palladin to stabilize the E-cadherin complex to the actin cytoskeleton in HCT116 cells. Alternatively, since palladin is also an actin-cross-linking protein that acts as a scaffold for multiple actin-binding proteins and signaling molecules, the loss of palladin may perturb actin dynamics which may in turn affect the formation and stabilization of adherens junctions. Down-regulation of Dial1 (58) and cortactin (59) both of which are involved in actin polymerization has previously been shown to be involved in the development and maintenance of adherens junctions.

Our study also highlights the importance of the Erk signaling pathway in the regulation of adherens junctions, cell morphology and palladin expression. The inhibition of this signaling pathway caused a complete reversion of the E1 mesenchymal to the parental HCT116 epithelial phenotype. Associated with this reversion, adherens junctions were reformed and palladin expression was restored in E1 cells. We also showed that palladin was required for the reversion to an epithelial phenotype. Knockdown of palladin expression using palladin specific siRNA abrogated the reversion induced by Erk inhibitor treatment, suggesting that palladin is required for the formation of adherens junctions in E1 cells. Hence, palladin expression is regulated by the Erk signaling pathway and its regulation mediates at least in part the effect of this pathway on adherens junction formation and cell morphology in E1 cells.

The loss of palladin and consequent disruption of adherens junction may have effects other than a change in morphology from an epithelial to a mesenchymal phenotype. The disruption of the E-cadherin/catenin complex releases β-catenin from the membranous pool, increasing its cytoplasmic pool. When not rapidly degraded, β-catenin can translocate into the nucleus to transactivate genes involved in tumor progression (60). Consistent with this hypothesis, some of the target genes of the β-catenin/TCF pathway such as BMP4, Sox9, Jag1 and Fn were up-regulated in the metastatic E1 cell line in our microarray study.

Our study shows a down-regulation of palladin in the more metastatic human colon cancer cell line E1 as well as in poorly-differentiated tumor tubules or dissociated tumor cells in primary colon tumors. We hypothesize that the down-regulation of palladin occurs early in the metastatic cascade, allowing cells to detach from the tumor mass and invade into the stroma. There are few studies on the expression of palladin in cancers. Palladin was found to be up-regulated in invasive cells compared with non-motile cells in a mouse xenograft tumor model where human breast tumor cells were induced to migrate using growth factors (61). A recent study showed that palladin levels in breast cancer patients are higher in malignant tissues than in normal breast samples. The authors also showed that palladin expression was higher in the more invasive breast cancer cell lines, where it was thought to play a role in podosome (matrix-degrading structures) formation (62). Serial analysis of gene expression (SAGE) of pancreatic and colorectal cancers at invasive sites, comprising both epithelial and stromal elements, identified palladin to be within a cluster of invasion-specific genes (63). However, in a separate report by Salaria et al., it was found that palladin expression levels were comparable between pancreatic cancer cells and non-neoplastic pancreatic cells, with high expression levels predominantly seen in non-neoplastic stromal fibroblasts of pancreatic tumor sections (64). These previous reports showing an up-regulation of palladin with increased invasion is invariant to our observation that loss in palladin expression is associated with increased invasiveness in colon rectal cancer. It is possible that there are tumor specific differences in the role and regulation of palladin in different cancers. Alternatively, it may also be possible that palladin is regulated differently at different stages of the metastatic cascade. For example, it may be down-regulated early on to allow cells to detach, but up-regulated later to allow cells to colonize the metastatic site.

In summary, the study has provided evidence for the involvement of palladin in adherens junction formation of epithelial colorectal cancer cell line HCT116 and demonstrated a link between palladin and the Erk signaling pathway in regulating the transition of cells from an epithelial to mesenchymal phenotype. Given the significance of these processes in cancer progression, it will be important to better define the role of palladin in these processes.

Acknowledgements

This study was funded by National University of Singapore Academic Research Fund Grant (ARF/R-185-000-074-112, Shing Chuan Hooi), and National Medical Research Council (NMRC/EDG/0003/2007, Shing Chuan Hooi).

References


